Health‐related quality of life
All‐cause mortality
HbA1c (%)
AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading to discontinuation
Insulin detemir showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).
1 finding from 1 review
RR 0.88 [0.64, 1.2]
1 study · 8 participants
Moderate
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3) Progression in retinopathy (4) Amputations (5) ESRD
It is very uncertain whether insulin detemir changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 1.5 [0.68, 3.32]
1 study · 2 participants
Very low
Hypoglycaemic episodes
It is very uncertain whether insulin detemir changes hypoglycaemic episodes (1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 0.45 [0.17, 1.2]
1 study · 5 participants
Very low
Mortality ‐ not reported · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life and treatment satisfaction ‐ not reported · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (glycated haemoglobin), change · patients with type 2 diabetes mellitus
1 finding from 1 review
Percentage of participants having at least one severe hypoglycaemic event · patients with type 2 diabetes mellitus
Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one severe hypoglycaemic… compared with insulin glargin (control) (low certainty).
1 finding from 1 review
Percentage of participants having at least one hypoglycaemic event · patients with type 2 diabetes mellitus
Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one hypoglycaemic event compared with insulin glargin (control) (low certainty).
1 finding from 1 review
Weight gain · patients with type 2 diabetes mellitus
1 finding from 1 review
Injection‐site reaction Rates of patients · patients with type 2 diabetes mellitus
Insulin detemir (intervention) may leads to higher percentage of participants having at least one injection site reaction compared with insulin glargin (control) (low certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe hypoglycaemia
It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).
1 finding from 1 review
Non‐fatal myocardial infarction/stroke
1 finding from 1 review
Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring 00:01‐05:59 (Davies 2014) or 23:00‐07:00 (BEGIN Young)
It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review